R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Inclusion Criteria: Histologically confirmed high-risk neuroblastoma that has relapsed or is refractory to standard therapy No active brain metastases Previously treated brain metastases allowed if there is no requirement for corticosteroids or anticonvulsants Performance status - Karnofsky performance status 70-100% or Lansky score ≥ 70 for your pediatric patients More than 3 months WBC at least 3,000/mm^3 Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Bilirubin normal (unless due to documented Gilbert's syndrome) Creatinine less than 1.5 times upper limit of normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other concurrent uncontrolled illness that would preclude study participation No ongoing or active infection No psychiatric illness or social situation that would preclude study participation No prior allergic reaction to compounds of similar chemical or biological composition to study drug (e.g., flurbiprofen or ibuprofen) No HIV-positive patients No concurrent biologic agents At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) No other concurrent chemotherapy See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent palliative radiotherapy See Disease Characteristics Recovered from all prior therapy No other concurrent investigational agents No concurrent commercial agents or therapies directed at malignancy No concurrent combination anti-retroviral therapy for HIV-positive patients